Literature DB >> 11673593

The effects of APOE genotype on age at onset and progression of neurodegenerative diseases.

J Chapman1, A D Korczyn, D M Karussis, D M Michaelson.   

Abstract

APOE genotype influences the age at onset of some neurodegenerative diseases such as AD and the rate of progression in others such as MS. The authors hypothesize that APOE genotype ubiquitously determines the efficacy of neuronal maintenance and repair in these diseases and that the seemingly divergent clinical effects are due to the stage of disease at which the diagnosis is made. Early diagnosis facilitates the measurement of effects on disease progression rate, whereas late diagnosis results in a marked effect of APOE genotype on disease onset.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11673593     DOI: 10.1212/wnl.57.8.1482

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  18 in total

Review 1.  Normal genetic variation, cognition, and aging.

Authors:  P M Greenwood; Raja Parasuraman
Journal:  Behav Cogn Neurosci Rev       Date:  2003-12

2.  Traumatic brain injury history is associated with earlier age of onset of frontotemporal dementia.

Authors:  Christian LoBue; Kristin Wilmoth; C Munro Cullum; Heidi C Rossetti; Laura H Lacritz; Linda S Hynan; John Hart; Kyle B Womack
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-09-10       Impact factor: 10.154

3.  Selective effect of Apo e4 on CA3 and dentate in normal aging and Alzheimer's disease using high resolution MRI at 4 T.

Authors:  S G Mueller; N Schuff; S Raptentsetsang; J Elman; M W Weiner
Journal:  Neuroimage       Date:  2008-04-22       Impact factor: 6.556

Review 4.  Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

Authors:  Cristina Politi; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Neuromolecular Med       Date:  2018-01-05       Impact factor: 3.843

5.  An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation.

Authors:  Christine M Bojanowski; Defen Shen; Emily Y Chew; Baitang Ning; Karl G Csaky; W Richard Green; Chi-Chao Chan; Jingsheng Tuo
Journal:  Environ Mol Mutagen       Date:  2006-10       Impact factor: 3.216

6.  Clinical Features of Alzheimer Disease With and Without Lewy Bodies.

Authors:  Eun Joo Chung; Ganesh M Babulal; Sarah E Monsell; Nigel J Cairns; Catherine M Roe; John C Morris
Journal:  JAMA Neurol       Date:  2015-07       Impact factor: 18.302

Review 7.  Family history and APOE-4 genetic risk in Alzheimer's disease.

Authors:  Markus Donix; Gary W Small; Susan Y Bookheimer
Journal:  Neuropsychol Rev       Date:  2012-02-23       Impact factor: 7.444

Review 8.  A tale of two systems: Lessons learned from female mid-life aging with implications for Alzheimer's prevention & treatment.

Authors:  Aarti Mishra; Yiwei Wang; Fei Yin; Francesca Vitali; Kathleen E Rodgers; Maira Soto; Lisa Mosconi; Tian Wang; Roberta D Brinton
Journal:  Ageing Res Rev       Date:  2021-12-17       Impact factor: 10.895

9.  The alternative splicing of the apolipoprotein E gene is unperturbed in the brains of Alzheimer's disease patients.

Authors:  James D Mills; Pamela J Sheahan; Donna Lai; Jillian J Kril; Michael Janitz; Greg T Sutherland
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

10.  Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology.

Authors:  Salvatore Oddo; Antonella Caccamo; David Cheng; Frank M LaFerla
Journal:  Brain Pathol       Date:  2008-07-24       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.